In The News

In Bloomberg Law, Joshua Oyster Discusses Appeals Court Ruling Applying Restrictions to Abortion Drug Access

Practices: FDA Regulatory, Health Care, Biomedical Research: Human, Animal and Bench Science, Health Privacy & Security, Risk Management, Regulatory Enforcement & Civil Litigation, Litigation, Appellate & Supreme Court Industries: Healthcare & Life Sciences

In a Bloomberg Law article, life sciences regulatory & compliance partner Joshua Oyster discussed the recent Fifth Circuit federal appeals court ruling that abortion pill mifepristone will remain available to patients but with restrictions. However, the decision will remain on hold pending an expected review by the U.S. Supreme Court.

Joshua notes that it is unclear how the manufacturers of the brand-name and generic versions of mifepristone would update product labeling, as well as safety materials and processes, to follow the court’s order.

Cookie Settings